Itàlia - italià - Ministero della Salute

bayer ag - spirotetramat; - sospensione concentrata - 4.53 g i valori indicati sono per 100 g di prodotto. - spirotetramat; 4.53%; (48; g/l) - insetticida

Unió Europea - italià - EMA (European Medicines Agency)

alfasigma s.p.a. - piperaquine tetraphosphate, artenimol - malaria - antiprotozoari - eurartesim è indicato per il trattamento della malaria da plasmodium falciparum non complicata negli adulti, nei bambini e nei bambini di età pari o superiore a 6 mesi e del peso di 5 kg o più. dovrebbero essere prese in considerazione le linee guida ufficiali sull'uso appropriato degli agenti antimalarici.

Unió Europea - italià - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artrite, reumatoide - immunosoppressori - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 e 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

curatis ag - primidonum - compresse - primidonum 250 mg, povidonum, gelatina, carmellosum calcicum, magnesii stearas, acidum stearicum pro compresso. - antiepilepticum - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

alfasigma schweiz ag - betamethasonum - compresse - betamethasonum 0.5 mg ut betamethasoni natrii phosphas, natrii hydrogenocarbonas, dinatrii citras sesquihydricus, povidonum, saccharinum natricum, e 211 6 mg, e 127, pro compresso corresp. natrium 22.23 mg. - glukokortikosteroid-therapie - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

pierre fabre pharma sa - ferro(ii) - retardtabletten - ferrum(ii) 80 mg ut ferrosi sulfas desiccatus, maltodextrinum, cellulosum microcristallinum, ammonio methacrylatis copolymerum a, ammonio methacrylatis copolymerum b, triethylis citras, talcum, glyceroli dibehenas, Überzug: hypromellosum, cellulosum microcristallinum, acidum stearicum, triethylis citras, e 172 (rubrum), e 172 (flavum), e 171, pro compresso obducto. - anemia da carenza di ferro in caso di accertata carenza di ferro - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - prednisolonum - compresse rivestite con film - prednisolonum 5.00 mg, cellulosum microcristallinum, cellulosi polvere, lactosum monohydricum 135.28 mg, carboxymethylamylum natricum un corrisp. sodio 0,23 mg, magnesio stearas, silice colloidalis anhydrica, hypromellosum, macrogolum 4000, dimeticonum, e 200, per compresso haze. - glucocorticoidi-therapie - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - prednisolonum - compresse rivestite con film - prednisolonum 20,00 mg, cellulosum microcristallinum, lactosum monohydricum 114.28 mg, carboxymethylamylum natricum un corrisp. sodio 0,37 mg, magnesio stearas, silice colloidalis anhydrica, hypromellosum, macrogolum 4000, e 132, dimeticonum, e 200, per compresso haze. - glucocorticoidi-therapie - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - prednisolonum - compresse rivestite con film - prednisolonum 50.00 mg, cellulosum microcristallinum, lactosum monohydricum 91.58 mg, carboxymethylamylum natricum un corrisp. sodio 0,36 mg, magnesio stearas, silice colloidalis anhydrica, hypromellosum, macrogolum 4000, e 172 (giallo), dimeticonum, e 200, per compresso haze. - glucocorticoidi-therapie - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - tamoxifenum - compresse rivestite con film - tamoxifenum 20 mg ut tamoxifeni citras, lactosum monohydricum 234 mg, maydis amylum, gelatina, carmellosum natricum conexum, magnesii stearas, hypromellosum, macrogolum 300, e 171, pro compresso obducto corresp. natrium 0.683 mg. - oncologicum - synthetika